Want to see IN:MANKIND full AI Analyst Report?
Top Page
Mankind Pharma Ltd.
(MANKIND)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹2,492.00
▼(-0.53% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily supported by solid underlying financial performance (steady revenue growth, healthy margins, improving leverage), but is held back by weak technical momentum (below key moving averages with negative MACD and low RSI/Stoch) and an expensive valuation (P/E ~48 with a low dividend yield).
Positive Factors
Consistent Revenue Growth
Sustained revenue growth indicates continuing demand across Mankind Pharma’s branded prescription and consumer healthcare portfolio. Its broad therapy coverage and distribution reach can support further expansion while reducing reliance on any single product category.
Negative Factors
Margin Compression
The decline in both net and EBIT margins suggests higher costs, weaker product mix or increased competitive pressure. If sustained, margin erosion could limit the benefit of revenue growth and reduce funds available for reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained revenue growth indicates continuing demand across Mankind Pharma’s branded prescription and consumer healthcare portfolio. Its broad therapy coverage and distribution reach can support further expansion while reducing reliance on any single product category.
Read all positive factors
Mankind Pharma Ltd. (MANKIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹959.00B
Dividend Yield0.04%
Average Volume (3M)52.82K
Price to Earnings (P/E)46.7
Beta (1Y)0.57
Revenue Growth13.75%
EPS Growth6.23%
CountryIN
Employees20,451
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)49.49
Shares Outstanding412,995,970
10 Day Avg. Volume67,454
30 Day Avg. Volume52,818
Financial Highlights & Ratios
PEG Ratio-7.55
Price to Book (P/B)5.08
Price to Sales (P/S)5.80
P/FCF Ratio43.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,659.25Price Target Upside6.14% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)57.2
Revenue Forecast (FY)₹160.54B
Mankind Pharma Ltd. Business Overview & Revenue Model
Company Description
Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its p...
How the Company Makes Money
Mankind Pharma primarily makes money by selling pharmaceutical and consumer healthcare products, with revenue largely driven by (1) domestic branded prescription formulations and (2) consumer healthcare/OTC brands.
1) Domestic branded prescriptio...
Mankind Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
66
Positive
Cash Flow
73
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.38B | 142.78B | 122.07B | 102.59B | 87.49B | 77.82B |
| Gross Profit | 74.80B | 61.55B | 86.38B | 70.02B | 57.87B | 53.12B |
| EBITDA | 40.31B | 38.58B | 35.58B | 28.04B | 20.37B | 21.97B |
| Net Income | 20.43B | 19.13B | 19.91B | 19.13B | 12.82B | 14.33B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 280.80B | 277.60B | 119.63B | 97.15B | 91.48B |
| Cash, Cash Equivalents and Short-Term Investments | 22.08B | 20.20B | 22.45B | 34.56B | 15.29B | 12.79B |
| Total Debt | 0.00 | 63.12B | 85.11B | 2.07B | 1.70B | 8.73B |
| Total Liabilities | -165.61B | 115.18B | 131.91B | 23.87B | 20.67B | 28.31B |
| Stockholders Equity | 165.61B | 163.00B | 143.32B | 93.63B | 74.35B | 61.55B |
Cash Flow | ||||||
| Free Cash Flow | 13.66B | 18.90B | 19.53B | 17.70B | 9.53B | -14.26B |
| Operating Cash Flow | 16.37B | 25.16B | 24.13B | 21.52B | 17.85B | 9.20B |
| Investing Cash Flow | -11.68B | -2.54B | -126.92B | -20.82B | -10.54B | -13.69B |
| Financing Cash Flow | -5.49B | -22.89B | 102.33B | 52.66M | -7.40B | 6.05B |
Mankind Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹962.54B | 17.39 | ― | 0.85% | 28.19% | 49.25% | |
69 Neutral | ₹4.56T | 37.41 | ― | 0.85% | 11.41% | 16.62% | |
66 Neutral | ₹619.35B | 28.74 | ― | 1.02% | 13.36% | -5.66% | |
63 Neutral | ₹1.87T | 76.97 | ― | 0.30% | 32.85% | 8.94% | |
59 Neutral | ₹959.00B | 46.66 | ― | 0.04% | 13.75% | 6.23% | |
57 Neutral | ₹1.15T | 25.53 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:MANKIND
Mankind Pharma Ltd.
2,305.85
-302.95
-11.61%
IN:ALKEM
Alkem Laboratories Ltd.
5,185.35
-83.27
-1.58%
IN:LUPIN
Lupin Limited
2,112.00
148.59
7.57%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,881.10
301.88
19.12%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,962.75
1,400.99
39.33%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,150.00
111.58
10.75%
Mankind Pharma Ltd. Corporate Events
Mankind Pharma Realigns NCD Security Cover, Frees Pledge on Bharat Serums Stake
Aug 17, 2026
Mankind Pharma has completed a realignment of the security cover backing its outstanding non-convertible debentures, following approvals from debenture holders and BSE. The company has created revised security over tangible and intangible assets o...
Mankind Pharma Board Clears Q1 FY27 Results and BSV Corporate Guarantee
Jul 30, 2026
Mankind Pharma’s board has approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, which have been reviewed by joint statutory auditors in line with Indian accounting standards and securities ...
Mankind Pharma to Exit Non-Core Unit, Sets Up Dutch Arm for Niche R&D
Jul 11, 2026
Mankind Pharma’s board has approved the divestment of its entire stake in Broadway Hospitality Services, a wholly owned subsidiary that contributed a negligible share of revenue and net worth, as part of its strategy to exit non-core assets....
Mankind Pharma Reshapes HR Leadership, Appoints Nilesh Kulkarni as Senior Management
Jun 8, 2026
Mankind Pharma Limited has undertaken an internal organisational restructuring of its human resources leadership, appointing senior HR professional Nilesh Kulkarni as Head of Human Resource Functions for the Mankind Pharma Group and designating hi...
Mankind Pharma Overhauls HR Leadership, Names Nilesh Kulkarni Group HR Head
Jun 8, 2026
Mankind Pharma has restructured its human resources leadership, appointing seasoned HR executive Nilesh Kulkarni as head of HR functions for the group and designating him as senior management personnel. The move, approved by the board on June 8, 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.